Emerald Advisers LLC Has $50.36 Million Stake in Insmed Incorporated (NASDAQ:INSM)

Emerald Advisers LLC grew its position in shares of Insmed Incorporated (NASDAQ:INSM) by 7.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 689,807 shares of the biopharmaceutical company’s stock after buying an additional 49,540 shares during the quarter. Insmed comprises about 2.0% of Emerald Advisers LLC’s investment portfolio, making the stock its 5th largest position. Emerald Advisers LLC’s holdings in Insmed were worth $50,356,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of INSM. Van ECK Associates Corp bought a new position in Insmed in the third quarter worth about $9,138,000. Harbor Capital Advisors Inc. bought a new position in Insmed in the third quarter worth about $1,291,000. US Bancorp DE raised its stake in Insmed by 55.3% in the third quarter. US Bancorp DE now owns 7,932 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 2,824 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Insmed by 74.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 33,052 shares of the biopharmaceutical company’s stock worth $2,413,000 after buying an additional 14,110 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in Insmed by 88.4% in the third quarter. Nisa Investment Advisors LLC now owns 3,350 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 1,572 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently issued reports on INSM shares. TD Cowen increased their price target on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group upped their price objective on shares of Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Morgan Stanley upped their price objective on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a report on Friday. Finally, StockNews.com cut shares of Insmed from a “hold” rating to a “sell” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average price target of $83.07.

Insmed Price Performance

Shares of NASDAQ INSM traded up $1.04 during mid-day trading on Friday, reaching $68.32. The company’s stock had a trading volume of 1,617,227 shares, compared to its average volume of 1,096,821. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The stock has a 50-day moving average of $73.03 and a two-hundred day moving average of $61.51. The stock has a market capitalization of $11.74 billion, a P/E ratio of -12.31 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. The business’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.10) EPS. On average, equities research analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the sale, the insider now directly owns 67,856 shares in the company, valued at $5,045,093.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares in the company, valued at approximately $7,157,150. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.